Bet Inhibitors Potentiate Activation Of P53 And Killing Of Aml By Mdm2 Inhibitors - A Candidate Combination Therapy

Peter D. Adams,Anne Louise Latif,Ashley Newcombe,Neil Robertson,Maria Terradas,Helen Stewart,Claire Reid,Loveena Rishi Delori,Timothy Chevassut,Xu Huang,Karen Keeshan,Karen Blyth,Mhairi Copland

BLOOD（2018）

引用 1|浏览10

暂无评分

摘要

In 2016, there will be approximately 19,950 new cases of Acute Myeloid Leukaemia (AML) in the United States. After diagnosis, five-year survival is currently ~26%, with available therapeutic approaches. Therefore, there remains a critical requirement for novel therapies for AML.

查看译文

关键词

mdm2 inhibitors,p53,aml,combination therapy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要